Monday, November 06, 2017

CBI’s 15th Specialty Therapies – A Forum for Payers

CBI’s 15th Specialty Therapies – A Forum for Payers
January 25-26, 2018 | Las Vegas, NV

CBI announces that registration is open for the Specialty Therapies Forum!

Join stakeholders from across the healthcare industry – health plans, PBMs, pharmacies, and drug manufacturers – to take a deep dive into managing cost, expanding access and improving patient services and care delivery for specialty therapies.

Exchange ideas on:
  • Latest trends for conquering diseases that were once considered untreatable
  • Addressing the challenges of controlling costs
  • Providing access for new therapies
  • And more!
Sign up to receive the agenda here. Visit for further details and to register.

Drug Channels readers will save $500 off of the standard rate when you use discount code QQQ952 and register prior to November 22nd.*

CBI will see you there!

More reasons to attend!

“Class act!” - Director of Specialty Pharmacy Programs, Blue Cross Blue Shield South Carolina

“I found the program to be well-designed and stimulating, well worth my time.” -Executive Director, MidAtlantic Business Group on Health

“The specialty pharmacy arena is constantly evolving. Quality Conferences like CBI’s Specialty Therapies Forum for Payers allows payers and industry alike to hear from KOL’s and prepare for the challenges that they are currently dealing with or will be facing in the near future.” -Director, Clinical Pharmacy, Blue Cross Blue Shield of Tennessee

“The conference provided a unique insight into the payer viewpoint and allowed attendees to observe complex discussions between interested parties.” -Manager of Specialty Clinical Services, Fairview Specialty Pharmacy

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rate or non-profit rates. Other restrictions may apply.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

No comments:

Post a Comment